Background
chronic disorder, heartburn, GERD, acid regurgitation, Barrett’s esophagus [HIP1601, esophagitis, Barrett’s esophagus, reflux of gastric
CHRONIC DISORDER, ESOPHAGEAL STRICTURE, GERD, ESOPHAGITIS, GASTROESOPHAGEAL REFLUX DISEASE (GERD), COMPLICATIONS
Gastroesophageal reflux disease (GERD) is a chronic disorder caused by the reflux of gastric contents, resulting in symptoms such as heartburn and acid regurgitation as well as potential complications such as esophagitis and Barrett’s esophagus [Proton pump inhibitors (PPIs) are the most commonly prescribed class of medications to treat GERD. They function by inhibiting the secretion of hydrogen ions through the inhibition of H+/K+-ATPase (a proton pump) located on the secretory surface of gastric parietal cells, resulting in a potent inhibition of gastric acid secretion and a sustained increase of intragastric pH. Previous studies have consistently demonstrated the superiority of PPIs over other acid blockers and placebo in controlling GERD symptoms and preventing complications such as esophagitis, esophageal stricture, and Barrett’s esophagus [HIP1601 is a newly developed esomeprazole formulation with dual delayed-release emission. It comprises a mixture of two types of enteric-coated granules designed to dissolve at different pH levels. Compared to conventional delayed-release PPIs, HIP1601 has an extended duration of therapeutic plasma drug concentration and is expected to improve the efficacy of GERD treatment [This study aimed to demonstrate that the clinical efficacy and safety of HIP1601 40 mg are non-inferior to those of HGP1705 (delayed-release esomeprazole, Nexium®) 40 mg in patients with GERD.